Ozempic Intestinal Blockage Warnings Added to FDA Label About Gastrointestinal Risks
FDA label warning update comes amid growing number of lawsuits over Ozempic intestinal side effects, involving users left with stomach paralysis or gastroparesis
FDA label warning update comes amid growing number of lawsuits over Ozempic intestinal side effects, involving users left with stomach paralysis or gastroparesis
Plaintiff indicates she was hospitalized for several days this summer due to Wegovy gastroparesis injuries.
Plaintiff indicates he suffered an Ozempic overdose after Giant pharmacy accidentally gave him four times the prescribed dosage of the diabetes drug.
Novo Nordisk's findings come as a growing number of users of the weight loss drug are now evaluating potential Wegovy lawsuits over the drug maker's failure to warn about stomach paralysis risks.
Although Eli Lilly's recently introduced diet drug has seen rapid sales growth, a new Mounjaro lawsuit alleges that users are not adequately warned about gastrointestinal side effects that may cause stomach paralsysis
Three cases of suicidal ideation have been reported in Iceland, all linked to Ozempic's active ingredient, semaglutide
The cancer-causing contaminant, a nitrosamine, was detected at levels exceeding the daily acceptable allowance set by the FDA, but there will be no recall due to fears of a shortage.
This is the first study to link metformin use to an increased risk of birth defects.
NDMA contamination has resulted in several major drug recalls in recent years, including Zantac and valsartan.